Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XR-NTX in HIV-infected opioid users (CHOICES Scale-Up)
NCT03275350Phase 3Completed
- Sponsor
- Oregon Health & Science University
- Start
- Feb 2018
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of naltrexone in opioid use disorder (OUD) (2 arms), sponsored by Oregon Health & Science University. Primary endpoint: Number of Participants With HIV Viral Suppression at 24 weeks. Started Feb 2018; status: completed.
02
Drugs
naltrexone
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT03275350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03275350.